Royal Columbian Hospital begins patient recruitment in Arch Biopartners’ Phase II trial of LSALT peptide targeting CS-AKI
🤖 D.R.A.F.T. Summary
Royal Columbian Hospital begins patient recruitment in Arch Biopartners’ Phase II trial of LSALT peptide targeting CS-AK
TORONTO, April 30, 2026 (GLOBE NEWSWIRE) — Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that Royal Columbian Hospital (RCH) has begun patient recruitment in the Company’s ongoing Phase II trial evaluating LSALT peptide as a new drug to prevent acute kidney injury in patients undergoing on-pump cardiac...
Outlets covering this story
Montreal Gazette
CENTER
Only one perspective covered this story — no diversity detected
Side-by-Side Outlet Comparison — Starter+
See how 1 outlets framed this story — bias by source, F.A.C.T. framing analysis, and verdict side by side.
Unlock with Starter →